Cambridge partners with Lilly in Open Innovation Drug Discovery Platform
The Cambridge Interprise website reports that the University of Cambridge is partnering with global pharmaceutical company Eli Lilly and Company in an active collaboration programme helping to find and develop potential new medicines, particularly in the areas of greatest need. Over 60 European institutions have so far joined the initiative, called the Open Innovation Drug Discovery Platform. The initiative aims to foster top talent in medical discovery, catering for the significant challenges researchers face in the current environment across Europe.
Click here to read the full article.